Puma Biotechnology
Post-IPO Equity - Puma Biotechnology - 2022-03-10 - Crunchbase Funding Round Profile
Puma Biotech granted Orphan Drug status for lung cancer candida | Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology falls more than 20%
PumaBiotech (@pumabiotech) / X
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology Inc (PBYI) Stock News | Stock Titan
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
Articles about Puma Biotechnology
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology
Jeff Ludwig posted on LinkedIn
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer | Business Wire
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology (PBYI) Price Target Increased by 5.26% to 5.10
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotechnology Receives Buy Rating and Shows Potential for Significant Growth - Best Stocks
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology shares gain on NERLYNX approval news | NASDAQ:PBYI
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
PumaBiotech (@pumabiotech) / X
Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
